Botulism

Joint venture wins $11M award to expedite production of botulinum vaccine

Published in Vaccine Weekly, October 1st, 2003

Computer Sciences Corporation (CSC) announced that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International, Inc., has been awarded an $11 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institutes of Health, for fast-track development of a heptavalent botulinum vaccine.

Under this award, DVC plans to develop the manufacturing processes for a safe and efficacious vaccine that will protect against all known forms of botulinum neurotoxins within 5 years. These processes would then be available for transition into pilot lot manufacture of the vaccine prior to phase I...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry